Liver Cancer Therapeutics - World Markets, 2023: CAGR is Projected to Grow at 8% - ResearchAndMarkets.com

September 4, 2018

DUBLIN--(BUSINESS WIRE)--Sep 4, 2018--The “Global Liver Cancer Therapeutics Market - Segmented by Therapy Area, End User, and Geography - Growth, Trends, and Forecast (2018 - 2023)” report has been added to ResearchAndMarkets.com’s offering.

The global liver cancer therapeutics market is expected to register a CAGR of around 8% during the forecast period (2018-2023).

Rising Incidence of Cancer

Liver cancer incidence has been rising in the US since the mid-1970s, and it is expected to continue to grow through till 2030. Change in the current lifestyle of individuals has led to the exposure of a large amount of population to the risk factors that contribute to liver cancer. The risk factors include hepatitis (caused by either the hepatitis B or hepatitis C virus), type 2 diabetes, metabolic disorders & excess body weight, alcohol consumption, and tobacco smoking.

It has also been shown that liver cancer risk increases substantially with the increase in one’s body mass index (BMI). More than half of the adult population in the US is overweight. Along with this high demand for therapeutic drugs for liver cancer, this creates great opportunities for manufacturers to produce more drugs and create a competitive landscape.

Other Key Highlights

Stringent Regulatory Policies for Therapeutics North America Dominates the Market

Major Development in the Market

Food and Drug Administration (FDA) granted accelerated approval to the immunotherapy drug nivolumab (Opdivo) for some patients with advanced liver cancer.

Companies Profiled

Alnylam Pharmaceuticals Inc. Onyx Pharmaceuticals Inc. F. Hoffmann-La Roche Ltd. Pfizer Inc. Arqule Inc. Jennerex Biotherapeutics Inc. Celsion Corp. Bayer Schering Pharma AG 4SC AG Bristol-Myers Squibb Company

Key Topics Covered

1. Introduction

2. Research Methodology

3. Executive Summary

4. Key Inferences

5. Market Overview

6. Drivers, Restraints, Opportunities and Challenges Analysis (DROC)

7. Market Segmentation

8. Competitive Landscape

9. Key Players

10. Future of the Market

For more information about this report visit https://www.researchandmarkets.com/research/8gd3vh/liver_cancer?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20180904005434/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Manager


For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Oncology Drugs



SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 09/04/2018 07:23 AM/DISC: 09/04/2018 07:23 AM


Update hourly